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Highlights 
 Reduced N-Acetylaspartate (NAA) in multiple regions, in posttraumatic stress 
disorder. 
 Reductions in NAA are Irrespective of atrophic change in the majority of studies.   
 Recent studies have found changes in excitatory and inhibitory neurotransmitters.  
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Abstract: 
Posttraumatic stress disorder (PTSD) is a trauma and stressor-related disorder that results in 
complex somatic, cognitive, affective and behavioural effects, after exposure to traumatic 
event(s). Conventional imaging (T1 and T2 weighted magnetic resonance imaging) has little 
to offer in the way of diagnosis of mental health conditions such as PTSD and there is 
currently no objective diagnostic test available. Magnetic resonance spectroscopy (MRS) 
allows for non-invasive measurement of metabolites and neurochemicals in the brain using 
a conventional MRI scanner and offers the potential to predict, diagnose and monitor PTSD. 
This systematic review summarises the results of 24 MRS studies, performed between 1998 
and 2017, to measure neurochemical differences, occurring as a consequence of PTSD. The 
most consistent finding in subjects with PTSD is lower N-acetylaspartate levels in the 
hippocampus and anterior cingulate cortex, with and without atrophic change. More recent 
studies, using more advanced techniques and modern hardware, have shown evidence of 
glutamatergic dysfunction and differences in gamma-aminobutyric acid levels in the brain of 
patients with PTSD. Conflicting results have been reported in choline-containing metabolites 
and there is emerging evidence of glutathione being affected. Myo-inositol and creatine are 
unchanged in the majority of studies.  
 
1 Introduction 
Posttraumatic stress disorder (PTSD) is a trauma and stressor-related disorder that results in 
complex somatic, cognitive, affective and behavioural effects, after exposure to traumatic 
event(s). PTSD is precipitated by a number of factors, including exposure to actual or 
threatened death or serious injury or a response to intense fear, helplessness or horror. 
PTSD is characterised by persistent re-experiencing of the traumatic event; avoidance of 
stimuli related to the trauma; and hyperarousal for at least one month post trauma 
(American Psychiatric Association, 1994), leading to significant psychosocial impairment for 
patients. PTSD is common in the general and military populations with an estimated 12-
month prevalence of 5.2% vs. 8.3%, respectively (McFarlane et al., 2010). 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
In vivo neuro proton magnetic resonance spectroscopy (MRS) provides a non-invasive 
measurement of metabolites in the brain using a conventional magnetic resonance imaging 
(MRI) scanner at a field strength of 1.5 or 3T. In vivo MRS can measure differences in 
parenchymal metabolism in both the healthy and diseased brain (Mountford et al., 2010) 
and has the potential to provide biomarkers for psychiatric disease, which often has no 
characteristic findings on conventional T1 and T2 weighted structural MRI (Foerster et al., 
2012; Murray et al., 2014). Up to 35 signals from metabolites, lipids, and macro-molecules 
can be measured using one dimensional (1D) neuro MRS at 3T (Provencher, 2001). 
Commonly used 1D MRS pulse sequences, include Point-RESolved Spectroscopy (PRESS) and 
Stimulated Echo Acquisition Mode (STEAM).  Shown below in Figure 1 is a typical 1D neuro 
MRS spectrum (3T using a 64-channel head coil) from a healthy human brain labelled with 
the most commonly measured metabolites. MRS has the potential to shed further 
information on the pathogenesis and mechanisms behind PTSD, particularly when state of 
the art scanners are employed, which measure neurotransmitters such as gamma-
aminobutyric acid (GABA), aspartate (Asp) and glutamate (Glu) non-invasively. This will 
further advance knowledge gained from other neuroimaging techniques such as functional 
magnetic resonance imaging (fMRI) and diffusion-weighted imaging (DWI). Additionally, in 
vivo neuro MRS is a promising technique that may help to predict patients at risk for PTSD 
and to non-invasively diagnose and monitor PTSD. 
 
In this review, we synthesize previous work utilising proton MRS to characterise metabolic 
differences in the brain of patients with PTSD. Also, we give researchers a broader 
background on key MRS metabolites and brain regions implicated in the pathogenesis of 
PTSD that will help inform research findings and conclusions. Finally, we aim to determine if 
certain metabolites correlate with clinical variables, to identify possible MRS biomarkers of 
disease severity. We conclude with a discussion on the limitations and outstanding 
challenges facing researchers, utilising MRS to investigate PTSD.  
 
1.1 Brain Regions Implicated in PTSD 
Multiple brain regions, specifically, the medial prefrontal cortex (mPFC), anterior cingulate 
cortex (ACC), amygdala, hippocampus and insular cortex have been implicated in the 
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pathogenesis of PTSD from imaging studies using positron emission tomography (PET), fMRI 
and structural MRI (Etkin and Wager, 2007; Lanius and Olff, 2017).  
 
1.1.1 Hippocampus 
The hippocampus is anatomically and functionally closely related to the amygdala; both 
structures play a significant role in the fear, fear extinction and anxiety networks, along with 
the hypothalamic-pituitary axis (Tovote et al., 2015), making the hippocampus an ideal 
region to interrogate with MRS.   
Initially, animal models were used to identify a relationship between stress and 
morphological change of the hippocampus. This damage may be the result of Glu toxicity, 
prolonged exposure to elevated glucocorticoids or differences in brain derived neurotrophic 
factors or a combination of all these factors (Magarinos et al., 1996; McEwen, 2000; 
McEwen et al., 1992; Sapolsky, 1996; Sunanda et al., 1995).  
Several volumetric meta-analyses have identified a reduction in hippocampal volume 
(Kitayama et al., 2005; Smith, 2005). Most recently O’Doherty et al. (2015) reviewed 36 
studies quantifying human hippocampal volume and found smaller volumes bilaterally in 
PTSD subjects, with a greater reduction in the left hippocampus. It is still unclear if 
hippocampal atrophy is congenital or acquired in PTSD; however, twin studies have 
provided early evidence that lower hippocampal volume may be a pre-existing risk factor for 
PTSD (Gilbertson et al., 2002). Spectroscopy has the potential to provide complementary, 
non-invasive metabolic measurement of the MR visible chemistry and neuronal integrity of 
the hippocampus and may identify these differences prior to structural MRI changes (Schuff 
et al., 2001). Currently, there are no prospective MRS studies that have aimed to determine 
if metabolic differences precede atrophy in PTSD.  
 
1.1.2 Amygdala 
The amygdala appears to play a key role in the pathogenesis and expression of PTSD. Fear 
conditioning relies on an interplay between the amygdala and the prelimbic cortex of the 
mPFC (Bauer, 2016). The amygdala is responsible for the association of conditioned and 
unconditioned stimuli and the mPFC is involved in the expression of fear memory (Alden et 
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al., 1994; Amorapanth et al., 2000). The amygdala is also critical in the extinction of fear 
memories, thought to occur within the basolateral amygdala (Amano et al., 2011).  
Functional MRI studies have identified increased activity within the amygdala in PTSD 
(Hughes and Shin, 2011). However, volumetric differences within the amygdala have been 
less clear cut; a recent meta-analysis concluded that there was no significant reduction in 
amygdala volume when trauma exposed controls were compared to PTSD subjects 
(O'Doherty et al., 2015). Yet the same meta-analysis identified smaller amygdala volumes 
bilaterally in PTSD subjects when compared to healthy controls (O'Doherty et al., 2015).  
 
There are technical challenges of acquiring spectroscopy of the amygdala due to its small 
size, measuring 1.2cm3 on average (Brabec et al., 2010). There are currently no MRS studies 
published on neurochemical differences in the amygdala in PTSD. However, one group has 
shown it is technically feasible to acquire MRS data from the amygdala (Nacewicz et al., 
2012). There are now clinical research scanners at 3T that may well allow MRS of this region 
to be evaluated. 
 
1.1.3 Medial Pre-Frontal Cortex 
The mPFC refers to the medial anterior frontal lobe parenchyma, a region with bidirectional 
white matter connections with the amygdala (Pape and Pare, 2010). The mPFC consist of 
two subregions: the prelimbic cortex (PL) and infralimbic cortex (IL), that in the rodent brain 
exert dual control over the amygdala, with the IL supporting fear expression and the PL 
supporting fear extinction. The human mPFC also contains the ACC, as shown in Figure 2. 
The human dorsal anterior cingulate cortex (dACC) is thought to be a functional homologue 
of the rodent PL (Milad and Quirk, 2012). The IL has been implicated in the expression of 
learned but not innate fear (Sierra-Mercado et al., 2011; Vidal-Gonzalez et al., 2006), and in 
humans the ventromedial pre-frontal cortex (vmPFC) is thought to function as the 
homologue of the IL (Milad and Quirk, 2012). Additionally, the mPFC appears to play a role 
in the cognitive processing of emotional tasks (Phan et al., 2004), integrating affective 
stimuli received via inputs from the amygdala and hippocampus and evaluating these inputs 
against previous experience and behavioural goals (Lanius and Olff, 2017).  
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1.1.4 Anterior Cingulate Cortex 
The cingulate cortex is located in the centre of the brain, anterior to the splenium of the 
corpus callosum. The anterior component of the cingulate cortex is subdivided into the 
dorsal, ventral and rostral components and two of these regions are shown in Figure 2. The 
dACC has been implicated in the expression and acquisition of conditioned fear responses 
(Milad et al., 2007).   
Higher resting state fMRI (rs-fMRI) and task-based activity (non-emotional tasks) has been 
identified in the dACC in PTSD patients and their non-traumatised twins (Shin et al., 2009), 
suggesting that higher rs-fMRI activity within the dACC may predispose for the development 
of PTSD. 
The rostral anterior cingulate cortex (rACC) has also been implicated in the pathogenesis of 
PTSD, where it has been shown to be hypoactive in fMRI studies, resulting in reduced 
amygdala inhibition (Shin and Liberzon 2010, Admon, Milad et al. 2013). Like the 
hippocampus, the ACC has been shown to have smaller volumes bilaterally in PTSD when 
compared to controls and these differences are thought to be acquired as a result of the 
disease (Kasai et al., 2008; Kitayama et al., 2006). There is also some evidence that the 
cortical thickness of the dACC correlates with the magnitude of a conditioned fear response 
(Hartley et al., 2011).  
 
1.1.5 Insula Cortex 
The insula cortex is located within the centre of the cerebral hemispheres and is extensively 
interconnected to regions, including the primary and secondary sensory cortex, anterior 
cingulate cortex, hippocampus, amygdala and the autonomic nervous system  (Augustine, 
1996).  The insula cortex has been associated with interoceptive awareness of negative 
emotion such as anticipatory anxiety of guilt (Phan et al., 2004) and has been shown to 
activate in response to fearful facial expressions (Calder et al., 2001) and fearful conditional 
stimuli (Sehlmeyer et al., 2009). Therefore, the insula cortex is well positioned to convey 
somatic sensations, displayed as higher autonomic activation, elicited by interoceptive 
negative emotion. In the meta-analysis undertaken by Etkin and Wager (2007), the insula 
and amygdala demonstrated higher activation in PTSD, a finding also noted in social anxiety 
disorder and specific phobia disorders, suggesting a common mechanism. Few studies have 
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investigated volumetric differences in the insula, however, two studies have identified lower 
gray matter density in PTSD subjects (Kasai et al., 2008; Nardo et al., 2010) and one study 
performed in twins, suggested the abnormality may be acquired in PTSD.  
 
1.2 Important brain metabolites 
Below, a brief introduction to the metabolites that have been implicated in PTSD is given.  
1.2.1 N-Acetylaspartate (NAA) 
NAA is an amino acid derivative present in the brain in high concentrations and provides the 
most intense singlet resonance at 2.01 ppm, in a proton MRS spectrum acquired from a 
healthy brain (Luyten and den Hollander, 1986; Moffett et al., 2007; Tallan, 1957; Tallan et 
al., 1956). The resonance is shouldered by the N-actelyaspartylglutamate (NAAG) singlet 
peak (Govindaraju et al., 2000).   
The function of NAA is an ongoing area of research, however, it is thought to function as an 
organic osmolyte. As an immediate precursor of NAAG, NAA acts as a source of acetate and 
facilitates energy metabolism in neuronal mitochondria (Moffett et al. 2007).  
Reduced NAA was first thought to indicate an irreversible loss of neuronal density. However, 
a decrease in NAA has been shown to be reversible in conditions such as acute brain injury 
or methamphetamine abuse (Maddock and Buonocore, 2012) and is thought to represent 
reversible neuronal or mitochondrial dysfunction (Moffett et al., 2007). Therefore, the 
proton MRS signal from NAA indicates the viability, health and density of neurons and 
therefore can indicate neuronal mitochondria dysfunction (Moffett et al., 2007). 
 
1.3 Glutamate and Glutamine 
Glutamate functions mainly as an excitatory neurotransmitter and is the most abundant 
amino acid in the human brain (6-13mmol     
  ) (Govindaraju et al., 2000; Ramadan et al., 
2013). The resonances of Glu and Gln are in the region of 3.74 – 3.75 ppm and 2.04-2.45 
ppm and are overlapped by Gln, GABA and NAA (Govindaraju et al., 2000). The chemical 
structures of Glu and Gln are very similar resulting in significant overlap in the spectra 
collected at 1.5, 3T and 4T but not at 7T (Terpstra et al., 2016), and for this reason the 
composite resonances are referred to as Glx at lower field strengths.  
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Gln is a precursor for the excitatory neurotransmitter Glu and is located within astrocytes 
(Govindaraju et al., 2000; Lin et al., 2015). The primary role of Gln is to act as the ‘storage 
form’ of amino acid neurotransmitters such as Glu and GABA. 
 
1.3.1 GABA 
GABA is the primary inhibitory neurotransmitter in the brain. It contains three methylene 
(CH2) groups that produce a complex one-dimensional spectrum with resonance multiplets 
centred at 1.89, 2.28 and 3.01 ppm. There is considerable overlap with resonances of NAA, 
Glu and creatine (Cr), which makes GABA difficult to reliably distinguish using conventional 
one-dimensional spectroscopy at 1.5 and 3T field strengths (Maddock and Buonocore 2012). 
It is important to remember that in a one dimensional MR spectrum the resonances are 
overlapping so the resultant difference may be due to other contributing molecules. 
Specialised pulse sequences are regarded as accurate ways to quantify GABA, the most 
common of which is MEGA-PRESS J–difference editing sequence (Mescher, Merkle et al. 
1998) and 2D JPRESS (Jensen et al., 2009). Alternatively, GABA can be measured in 
conventional short echo time (TE) MRS using a fitting algorithm, such as the one 
implemented in LCMODEL (Provencher, 1993). 
 
1.3.2 Myo-inositol (mI) 
Myo-inositol is the most abundant form of inositol found in the brain. Using proton MRS, mI 
has a prominent mutiplet peak at 3.52 and 3.61 ppm (Govindaraju, Young et al. 2000). It is 
thought to be a astroglial marker (Brand et al., 1993).  
 
1.3.3 Choline (Cho) 
Choline is a vital constituent of many phosphoglycolipids, present within cell membranes 
  oolman and   hm       , and contains contributions from glycerophosphorylcholine and 
phosphorylcholine. An increase in glycerophosphorylcholine and/or phosphorylcholine can 
indicate an increase in synthesis or breakdown of membrane phospholipids and results in a 
subsequent increase in the 3.21 ppm peak on proton MRS (Boulanger et al., 2000; Geddes 
et al., 1997). 
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1.3.4 Total Creatine (tCr) 
Total Cr gives rise to the second largest peak in a typical brain MR spectrum at 3.03 ppm and 
contains contributions from Cr and phosphocreatine (PCr). PCr is a precursor for ATP and 
therefore tCr is thought of as an in vivo mitochondrial energy marker. tCr has been shown 
to be relatively stable in the healthy brain, with no significant daily intrasubject variation 
and for that reason is often used as an internal reference for other metabolites (Saunders et 
al., 1999; Soreni et al., 2006). However, tCr been shown to be disturbed in pathologies that 
alter cell metabolism, such as stroke and malignancy (Howe et al., 2003; Mathews et al., 
1995) and is therefore used with caution as an internal reference metabolite.  
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2 Method 
2.1 Literature search and inclusion criteria 
A literature search was conducted using PubMed and PsychNet in April 2018 using the 
following keywords:  i  “post-traumatic stress disorder” and (ii) “PTSD” combined with the 
following subcategory keywords:  iii  “magnetic resonance spectroscopy” and  iv  “M S”. 
Studies were selected if they satisfied the following conditions: in vivo human MRS studies, 
the patient group had a Diagnostic and Statistical Manual (DSM) based diagnosis of PTSD, 
were written in English and were compared with either a healthy or traumatised control 
group that did not have PTSD. None of the studies included participants with severe 
traumatic brain injury. Where any two or more studies included the same or overlapping 
patient populations, only the study with the largest sample size was included. 
3 Results 
 A total of 27 studies were identified. Three studies were excluded: the study by De Bellis et 
al. (2001) was excluded as it was a case study with a single participant; the investigation 
performed by Henigsberg et al. (2011) as it was a therapeutic study and Neylan et al.’s 
(Neylan et al., 2003) study as it contained overlapping populations with Schuff et al.’s 
(Schuff et al., 2001) study. The remaining 24 studies were published between 1998 and 
2017 and are summarised below in Table 1. Metabolic findings relevant to PTSD are shown 
below. 
 
3.1 N-Acetylaspartate 
The most consistent MRS finding identified in PTSD was a reduction in NAA.   
 
Fifteen studies investigated NAA levels in the hippocampus. Several early studies refer to 
the to the hippocampus as the medial temporal, as the MRS voxel contained the 
hippocampus medial temporal lobe parenchyma.   Six studies used absolute quantification 
(studies 3, 5, 13, 14, 16, and 24) and half of these found no significant difference in NAA 
(studies 5, 14 and 16). The positive studies found a statistically significant reduction in NAA 
levels in both hippocampi. Study 5 found a trend toward lower NAA in the hippocampus (p = 
0.054), however, the sample was small and this may have limited its statistical power. 
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Eleven studies (1, 4, 6, 8, 9, 11, 12, 13, 14, 15 and 17) used Cr as an internal reference (some 
used both absolute and relative quantification). Four studies (6, 8, 12 and 13) identified no 
difference in the hippocampal NAA/Cr. One study (1) found higher NAA/Cr in the right 
hippocampus only, two studies (4 and 11) found lower NAA/Cr in the left hippocampus only 
and the remaining studies (9, 14, 15 and 17) found a significant reduction in NAA/Cr in both 
hippocampi.   
Several early studies hypothesised that reductions in NAA may precede morphological 
change in the hippocampus. Many studies (3, 9, 12, 14, 16, and 24) found no significant 
difference in hippocampal volume, while the majority of studies (1, 4, 5, 6, 8, 12, 13 and 15) 
did not quantify the hippocampal volume. Shu et al. (2013a) identified a significant 
reduction in the normalised left hippocampus along with a significant reduction in NAA/Cr 
and Li et al. (2006) found lower NAA/Cr was correlated with lower gray matter density in the 
left hippocampus.  
 
Eleven studies (2, 9, 10, 13, 14, 15, 18, 19, 20, 21 and 22) investigated NAA levels within the 
ACC. Several earlier studies (2, 10, 13, 14 and 15) did not specify the exact voxel location 
within the ACC, two of these studies (13 and 14) identified lower absolute NAA, and two 
studies found lower NAA/Cr (2 and 15). One study (9) reported lower NAA/Cr in the dACC 
when PTSD was compared to healthy controls and one other (19) reported no difference in 
NAA in the dACC, noting that study 19 compared PTSD to trauma exposed controls. One 
study in the rACC (21) identified lower absolute NAA, while the remaining three studies (19, 
20 and 22) investigating this region found no significant difference in NAA. No studies have 
explored the longitudinal change in metabolites in the ACC with PTSD. 
 
NAA was found to be lower in several other regions of the brain, including the left basal 
ganglia (Lim et al., 2003) and the parietal occipital gray matter (Meyerhoff et al., 2014). 
Otherwise, no significant difference in NAA was identified in the periventricular white 
matter (WM) (Lim et al., 2003), occipital gray matter and white matter (Seedat et al., 2005; 
Villarreal et al., 2002), right insula (Rosso et al., 2014), dorsolateral pre-frontal cortex 
(DLPFC) (Michels et al., 2014), posterior occipital cortex (POC) and temporal lobe 
(Meyerhoff et al., 2014; Pennington et al., 2014).   
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3.2 Glutamate and Glutamine 
It is possible that glutamatergic dysfunction reported in several brain regions plays a role in 
the pathogenesis of PTSD, however findings were mixed. It is worth noting that the accurate 
measurement of Glu and Gln as separate entities is currently only possible at the higher 
field strength of 7T (Terpstra et al., 2016). Six studies (19, 20, 21, 22, 23 and 24) investigated 
Glx levels in multiple brain regions. In the temporal lobe two studies (19 and 21) identified a 
reduction in Glx and Glu respectively. Furthermore, a study performed by Pennington et al. 
(2014) identified higher absolute Glx in the temporal lobe in PTSD participants with co-
morbid alcohol use disorder (AUD) when compared to PTSD participants without AUD. Only 
one study (22) identified a reduction in Glx within rACC using 1D MRS; where the authors 
noted that Glx was lowest in PTSD subjects followed by those in PTSD remission. Other 
investigators reported no difference in Glx in the ACC (studies: 19, 20, 21 and 23). More 
recently Rosso et al. (2017) quantified Glu and Gln in the hippocampus, using a novel TE 
averaging sequence 2D JPRESS; they found higher absolute Glu and Glu/NAA in the right 
hippocampus. Statistically significant absolute Glu concentration was positively correlated 
with re-experiencing symptoms and trauma dose was significantly positively correlated with 
right hippocampal NAA/Cr. No differences in Glu or Gln were identified in the POC or DLPFC 
(Meyerhoff et al., 2014; Michels et al., 2014; Pennington et al., 2014). 
 
3.3 GABA 
GABA was investigated in four studies (18, 19, 20 and 21). No difference in GABA/Cr was 
reported in the dACC (study 18), however, one study (20) identified higher GABA/Cr in the 
rACC and DLPFC. Lower GABA/Cr was noted within the insula in a single study (18) and 
lower absolute GABA in the POC and medial temporal lobe (study 21).  One study (19) found 
no difference in absolute GABA in the POC when PTSD participants were compared to 
healthy controls, however, they did find higher GABA when PTSD sufferers with AUD were 
compared to PTSD participants without AUD. All the studies described here used MEGA-
PRESS to quantify GABA within the brain.  
 
3.4 Myo-Inositol 
Only two studies (10 and 19) identified differences in mI in PTSD. Seedat et al. (2005) found 
higher mI/Cr in the ACC of participants who had PTSD secondary to intimate partner 
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violence. No other studies noted mI to be raised in the ACC. In a single study performed in 
PTSD patients with AUD, absolute mI was lower in the ACC when compared to trauma 
exposed controls (Pennington et al., 2014). Multiple studies (7, 13, 21 and 22) found no 
difference in mI in patients with PTSD, irrespective of brain region.  
 
3.5 Choline 
Twelve studies (1, 2, 7, 9, 10, 12, 13, 15, 17, 19, 21 and 22) have measured Cho containing 
compounds in PTSD.  The majority of studies (2, 9, 13, 21 and 22) found no difference in Cho 
containing compounds in the ACC and hippocampus (12, 13, 15, and 17). Conflicting results 
were reported by two studies (10 and 15) measuring Cho in the ACC using 1D MRS Seedat et 
al. (2005) found higher Cho/Cr in PTSD when compared to healthy and trauma exposed 
controls, while Guo et al. (2012) identified lower Cho/Cr in the ACC in PTSD compared to 
healthy controls in a large cohort. Conflicting results were also reported in the hippocampus 
(studies 1 and 9). Lower absolute Cho was found in the temporal lobe of participants with 
PTSD and AUD when compared to PTSD participants without AUD and trauma exposed 
controls (Pennington et al., 2014; Seedat et al., 2005).   
 
3.6 Glutathione 
One study (20) identified an increase in glutathione/Cr in the ACC and DLPFC in PTSD when 
compared to trauma exposed controls.  
 
3.7 Total Creatine 
Two early studies identified a reduction in absolute Cr in the hippocampus and occipital 
white matter (studies: 2 and 3). Four subsequent studies have identified no difference in 
absolute Cr concentration (studies 13, 18, 19 and, 21). 
 
3.8 Metabolic correlates 
Increased hippocampal exposure to glucocorticoids has been proposed as a cause of 
atrophy in PTSD. To explore the glucocorticoid hypothesis further, two studies correlated 
serum cortisol levels with hippocampal neuro-metabolites and found differing results. Shu 
et al. (2013b) identified a negative correlation between serum cortisol and hippocampal 
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NAA/Cr levels, whilst Neylan et al. (2003) (not listed in Table 1 due to overlap with Schuff et 
al.’s (Schuff et al., 2001) population) found a positive correlation between the two.   
 
Two studies have identified correlations with GABA and clinical outcomes in PTSD. 
Meyerhoff et al. (2014) noted that lower levels of GABA and higher Glu correlated with a 
higher insomnia severity index. In a small group of participants, Rosso et al. (2014) found 
lower levels of GABA were correlated with higher state-trait anxiety levels. However, they 
found no correlation between GABA and severity of symptoms (Rosso et al., 2014).   
 
Other reports identified a correlation with re-experiencing symptoms and NAA levels. Ham 
et al. (2017) identified lower levels of NAA in the ACC were correlated with re-experiencing 
symptoms and more recently, Rosso et al. (2017) found the same in the hippocampi of PTSD 
subjects. Shu et al. (2013b) noted a correlation between lower NAA/Cr levels in the 
hippocampus and higher total clinical administered PTSD scores (CAPs). Otherwise, no 
significant correlation between NAA and symptom severity was identified (Kimbrell et al., 
2005; Lim et al., 2003; Rosso et al., 2017).  
 
A positive correlation between absolute Glu levels in the right hippocampus and re-
experiencing symptoms was identified by Rosso et al (Rosso et al., 2017). Additionally, 
Harnett et al. (Harnett et al., 2017) found a positive relationship between dACC and 
absolute Glx levels and current and future stress disorder symptoms.   
 
A positive correlation was found between disease duration and the anti-oxidant glutathione 
levels (Michels et al., 2014). 
 
3.9 Confounding variables in PTSD research 
Current or past alcohol dependence is a common co-morbidity seen in PTSD that has been 
shown to result in significant differences when PTSD participants with and without AUD are 
compared (Pennington et al., 2014) and this is likely to be particularly important for GABA, 
NAA and Glx (Behar et al., 1999).  
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Multiple studies have controlled or adjusted for the effects of depression and medications 
(mainly serotonin re-uptake inhibitors) using a linear regression and have found no 
significant effect (Eckart et al., 2012; Kimbrell et al., 2005; Lim et al., 2003; Michels et al., 
2014). In addition, no significant reduction in NAA has been reported in the medial temporal 
lobe / hippocampus or hippocampi in depression (Rao et al., 2011).   
 
Many studies have specifically excluded participants with traumatic brain injury (TBI), given 
that these individuals may have a higher risk of PTSD, which can be related to the TBI or to a 
separate event (Bryant, 2001; Kennedy et al., 2007; King, 2008). None of the studies 
identified directly compared TBI and PTSD groups.  
 
Two studies compared PTSD subjects to traumatised and non-traumatised control groups 
(Eckart et al., 2012; Seedat et al., 2005), in an effort to determine if an observed effect was 
due to PTSD or simply trauma exposure. These studies have had mixed results; Seedat et al. 
(2005) found a significant difference between PTSD and trauma exposed control groups, in 
the ACC, suggesting that the observed metabolic difference was due to PTSD itself. On the 
other hand, Eckart et al. (2012) found no significant difference between the PTSD, healthy / 
trauma exposed control groups using bilateral hippocampal and insula voxels.    
4 Discussion 
The current systematic review has summarised findings from 24 proton MRS studies 
comparing PTSD subjects to controls subjects. There is emerging evidence of neurochemical 
abnormalities in patients with PTSD, identified using in vivo proton MRS of the human brain. 
It is important to note that the hardware and post-processing capabilities for in vivo neuro 
MRS have been steadily improving as early studies were restricted in what they were able to 
record. 
 
The most consistent findings to date are reductions in NAA in the region of the 
hippocampus and ACC. Multiple studies have found reductions in both absolute NAA and 
NAA/Cr in both hippocampi in PTSD participants when compared to healthy and trauma 
exposed controls. A meta-analysis of MRS studies performed by Karl et al. (2010) identified 
lower NAA in the left hippocampus when compared to healthy and trauma exposed controls 
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and lower right hippocampal NAA only when compared to trauma exposed controls. Two 
possible aetiologies are explained for the laterality of lower hippocampal NAA: the left 
hippocampus has a larger volume in right handed individuals and perhaps atrophies faster 
and the left hippocampus has a greater role in declarative memory (encoding and retrieving 
tasks) and declarative memory is known to be impaired in PTSD (Li et al., 2006). Since 
publication of Karl and Werner’s meta-analysis (Karl and Werner, 2010), there have been 
three additional studies published that have identified lower NAA/Cr (Guo et al., 2012; Shu 
et al., 2013) and lower total NAA (Rosso et al., 2017) in both hippocampi of PTSD 
participants. NAA can be reduced in the brain for multiple reasons (see ‘1.2 Important Brain 
Metabolites’ above), one of which is lower neuronal density, ultimately leading to 
morphologic change or atrophy. The findings of lower NAA within both hippocampi 
correlates with the meta-analyses of structural imaging studies (Kitayama et al., 2005; 
Smith, 2005). It is still not clear from the data published to date if the MRS differences 
(lower NAA) precedes morphological changes, however, this would appear very likely, given 
that multiple studies have identified lower hippocampal NAA without atrophic change. It is 
worth noting that a large number of studies identified no difference in hippocampal NAA 
despite the fact that almost all of these studies were performed on veterans and 
participants with long standing chronic PTSD. This may suggest that the reduction in 
hippocampal NAA is reversible in PTSD, as has been shown in conditions such as acute brain 
injury or methamphetamine abuse (Maddock and Buonocore, 2012), which is thought to 
represent reversible neuronal or mitochondrial dysfunction (Moffett et al., 2007) as 
described in the introduction. Additionally, the majority of the studies that found lower NAA 
in the hippocampi of those with PTSD compared to healthy controls, suggesting that the 
difference is not due to the choice of control cohort (trauma exposed vs. healthy control), as 
proposed by Karl et al. (Karl et al., 2006).  
 
A smaller number of studies have reported a reduction in NAA within the ACC with 
increased heterogeneity of results when compared to the hippocampus. However, many of 
the early studies did not specify the region of the ACC being measured. Studies that have 
reported NAA in the rACC have given mixed results, some with lower NAA and others with 
no difference. Differences in the rACC in PTSD are thought to be acquired and the disparity 
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in the MRS results may be due variations in metabolite concentrations over time (Admon et 
al., 2013). 
 
More recently, with advancing spectroscopic techniques, researchers have identified 
glutamatergic dysfunction and differences to GABA in some of the brain regions where we 
would expect hypoactivation, based on previous fMRI work, such as the occipital cortex and 
rACC.  In a study of adolescents exposed to earthquake, Yang et al. (Yang et al., 2015) found 
lower Glx/Cr in the rACC, in both PTSD and remitted PTSD. However, patients with PTSD had 
further lower rACC Glx/Cr when compared to remitted PTSD patients, suggesting lower rACC 
excitatory neurotransmission and therefore lower amygdala inhibition. However, this 
finding was not supported by Meyerhoff et al. (Meyerhoff et al., 2014), which may be due 
the  fluctuating of metabolic differences over time in this region. On the other hand, higher 
Glx has been identified in the rACC of patients with PTSD and comorbid AUD when 
compared to PTSD patients without AUD (Pennington et al., 2014) and with an associated 
increase in GABA in the same region (Meyerhoff et al., 2014), raising the possibility that 
alcohol reverses some of the differences described above and partly explains the association 
of PSTD and AUD. Higher GABA/Cr has been noted in the rACC.  
One hypothesis for higher GABA is overexpression of Glu or Gln decarboxylase and/or lower 
clearance of GABA from the synaptic cleft (Michels et al., 2014), which supports the 
hypothesis of rACC hypoactivation, resulting in amygdala hyperactivation (Admon et al., 
2013). More recently, higher absolute Glu was identified in the right hippocampus (Rosso et 
al., 2017) raising the possibility that reductions in volume and NAA within the hippocampus 
may be secondary to excitotoxicity. 
No difference in GABA or Glx have been identified in the dACC, noting that only a small 
number of studies have evaluated this region. fMRI studies have shown this region to be 
hyperactive in PTSD and the region may be congenitally abnormal in those who have a risk 
of developing PTSD. Future studies aiming to predict those at risk of developing PTSD may 
be able to further explore this region. 
 
A small number of studies have reported altered Cho levels in PTSD, but the results are 
inconsistent. The two studies that identified differences in Cho used relative measures and 
compared PTSD to healthy controls with conflicting results. One study found a reduction in 
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absolute Cho in the ACC in a population with comorbid AUD (Pennington et al., 2014). 
Alterations in Cho may be due to differences relating to glial cells (Seedat et al., 2005), 
white-matter or could reflect neuroinflammation (Rohleder and Karl, 2006). More work is 
needed to determine the directionality of differences in Cho containing compounds. 
 
Only one study investigated metabolic differences in the insula cortex, finding lower 
GABA/Cr with a significant negative correlation with state and trait anxiety. This finding 
correlates with previous fMRI studies that have identified increased insula cortex activation 
in PTSD, social anxiety and specific phobia disorders (Etkin and Wager, 2007).    
 
Increasing glutathione correlated with disease duration (Michels et al., 2014). Glutathione is 
an antioxidant that reduces reactive oxygen species, which can have a detrimental effect at 
a cellular level. It is not yet known if higher glutathione is a predisposing factor or acquired 
as the result of PTSD, however, mouse models have also shown overexpression of the genes 
glyoxalase 1 and glutathione reductase 1 results in higher anxiety, linking the glutathione 
cycle with anxiety behaviour in a mouse model (Hovatta et al., 2005).   
 
4.1 Limitations 
A challenge for all neuroimaging studies exploring PTSD is the heterogeneity of patient 
populations. PTSD is known to have multiple comorbidities such as Axis I and II disorders, 
including depression; alcohol and substance misuse and chronic pain (Scioli-Salter et al., 
2015). Additionally, the majority of patients with PTSD are taking medications, a factor that 
may confound interpretation of neurochemical differences (Lanius, 2010). These factors can 
make generalising the study results and determining unique metabolic differences in PTSD 
problematic. There is evidence that AUD alters brain metabolites (Schuff et al., 2008) and 
these participants with AUD should be excluded. Depression has not been shown to 
contribute to metabolic differences recorded in PTSD and co-morbid depression is so 
common in this group one could argue that excluding those with depression would result in 
an unrepresentative sample. Medications such as benzodiazepines and antipsychotics are 
highly likely to alter neuro-metabolites and should be controlled for. It is less clear if 
serotonin re-uptake inhibitors are used, but to date no significant difference has been 
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identified in participants using these drugs (as discussed in section 3.9). A limited number of 
studies have identified differences between PTSD, healthy control and trauma exposed 
groups and to ensure that the differences being identified can be attributed to PTSD alone 
most studies use a trauma exposed control group.  
 
Many of the early spectroscopic studies (55%) utilised a low field strength (1.5T), to 
measure metabolic differences in patients diagnosed with PTSD. There are inherent 
limitations in performing neurospectroscopy at low field, such as increased peak overlap; 
limiting the number of measurable metabolites. Additionally, many of the early studies used 
peak area or peak fitting with a limited basis set to quantify a limited number of 
metabolites, such as NAA, Cr and Cho, a technique that has now been superseded by peak 
fitting with more extensive basis sets and bioinformatics evaluation of the data point by 
point (Stanwell et al., 2010).  
 
Several early studies used a larger MRS voxel within the medial temporal lobe that included 
the hippocampus. The benefit of this approach is that signal to noise ratio is higher, the 
limitation is the spectrum contains contributions from surrounding medial temporal lobe 
parenchyma. As MRI hardware and techniques have improved, researchers have been able 
to reduce the MRS voxel size, whilst maintaining adequate signal-to-noise and improving 
the anatomical specificity of the MRS voxel. This difference in voxel volume and anatomic 
location, may also go some of the way to explaining the variability in MRS findings in the 
hippocampus. 
 
Finally, there is a large degree of methodological heterogeneity within studies due to the 
differing MRS pulse sequences available, such as PRESS and  STEAM for 1D and the 
availability of 2D magnetic resonance spectral imaging  (MRSI). To further complicate 
comparisons there are multiple ways in which data can be post-processed, evaluated and 
corrected. For example, fitted 1D MRS metabolite peaks can be referenced to an internal 
resonance such as Cr or referenced to tissue water concentration, known as absolute 
quantification. Some perform partial volume corrections. However, the spectroscopy 
community have recognised this limitation and recommended protocols for common use 
(Oz et al., 2014).  
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5 Conclusions and Future directions 
The most consistent MRS findings in PTSD is lower NAA in the hippocampi and ACC. The 
reduced NAA in these regions may be due to neuronal loss and early evidence suggests that 
reductions in NAA may proceed morphologic change.  On the other hand, multiple studies 
have demonstrated no difference in NAA, raising the possibility that reductions in NAA in 
PTSD may be reversible or fluctuate over time. Levels of NAA in the ACC and hippocampus 
have been found to correlate with clinical symptoms by some. There is emerging evidence 
of glutamatergic dysfunction in the hippocampus, occipital cortex and rACC and it is possible 
that higher levels of Glu in the hippocampus may be contributing to neuronal loss, 
secondary to excitotoxicity. Mixed differences have been found in GABA, which is not 
unexpected due to the dynamic nature of this metabolite. The majority of studies have 
found no change in mI or Cr, however caution is recommended when using Cr as an internal 
reference. Further work is required to determine the magnitude and direction of change in 
Cho containing compounds in PTSD, which to date appear to be reduced or unchanged. A 
single study has measured glutathione, suggesting an increase in PTSD.  MRS studies have 
been able to identify metabolic changes in the brains of patients with PTSD, a condition that 
has no conventional imaging findings. Ongoing work is required to further characterise 
these differences, whilst attempting to maximising the generalisability of results. 
 
Many of the early spectroscopic studies were limited by hardware. In the last decade, there 
have been multiple technological leaps in both MR scanner technology, shimming and 
acquisition protocols (Oz et al., 2014). Higher magnetic field strengths allow for higher signal 
to noise and greater peak separation, improving comparative accuracy. The newer 
hardware has made techniques such as 2D and 3D MRSI, highly relevant to the study of 
PTSD. High spatial resolution 3D MRSI, performed at high field strengths (3 and 7T), will 
allow for measurement of metabolites in brain regions such as the amygdala (a region that 
it yet to be examined due to its small volume), insular cortex and the hippocampus. 
Additionally, k-space under sampling can be utilised to accelerate the acquisition of 3D 
MRSI, lowering acquisition times. Two-dimensional MR spectroscopy is a technique that 
allows overlapping and composite metabolic peaks to be deconvoluted (Ramadan et al., 
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2011; Thomas et al., 2003); it has been now applied to several pathologies and offers 
further metabolic insights not available using 1D MRS alone (Lin et al., 2015; Ramadan et al., 
2011; Ramadan et al., 2015).  However, it is yet to be applied to the condition of PTSD and 
may allow identification of novel biomarkers that have not been identified using 1D MRS.  
 
Another promising technique, which is yet to be applied to PTSD is functional MRS (fMRS). 
fMRS is a technique that characterises the regional and temporal change of 
neurotransmitters whilst subjects are exposed to a stimulus, as in fMRI which measures 
differences in blood oxygen level. This technique is highly relevant to PTSD and may yield 
further insights into the pathogenesis of the condition. For example, fMRS could be applied 
to the hippocampus, using a learning task, in participants with PTSD to further evaluate 
differences in glutamatergic modulation within the hippocampus.  Finally, fMRS may 
improve MRS reproducibility, by controlling for behaviour, potentially reducing the 
variability of studies quantifying neurotransmitters. 
 
Machine learning techniques are providing a more sophisticated and tailored means of 
evaluation of the complex, but rich data available from in vivo 1D and 2D neuro MRS, as well 
as the evaluation of multimodal MRI data. Machine learning techniques may improve the 
specificity and sensitivity for evaluation of the PTSD condition when using MRS. Machine 
learning techniques have been used in the past for the analysis of 1D MRS evaluating 
chronic pain and primary brain lesions (Ranjith et al., 2015; Stanwell P et al., 2010), 
increasing the specificity of MRS for detecting these conditions, but as yet have not been 
applied to PTSD.  
 
There is a need for further prospective studies in the field of PTSD using advanced neuro 
MRS, techniques. These studies should aim to answer the following questions: does lower 
hippocampal volume predispose to PTSD; does metabolic differences in the hippocampus 
proceed atrophy?; are there MRS differences in the dACC that predispose to PTSD and are 
rACC and insular cortex MRS differences acquired as part of the condition?.   
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Study Voxel Location/ Size Field / Sequence / TR (s) / TE 
(ms) / averages 
Participants Exclusion Criteria Trauma Psychological 
Assessment 
Mean CAPS Findings Comments 
1 (Freeman et al., 1998) Hippocampi / 20 x 20 x 30 
mm3 
1.5T / STEAM / 2 / 30 / 128 21 PTSD subjects 
8 veteran controls. 
Head injury 
Dementia 
Cognitive impairment.  
Combat related trauma CAPS 
SCID 
NG Right hippocampus:  NAA/Cr ratio 
Left hippocampus:   Cho/Cr 
 
Did not control for 
alcohol, substance 
dependence or 
handedness. 
 
Comorbid major 
depression.  
 
Matched for age and 
education.  
 
No PV correction. 
 
SPARC workstation for 
calculation of peak 
ratios.  
2 (De Bellis et al., 2000) ACC / 20 x 15 x 10 mm3 1.5 / STEAM / 1.5 / NG / 150 Children and Adolescents 
 
11 PTSD subjects. 
11 Healthy controls.  
 
Matched for age, sex and IQ. 
2 subjects left handed.  
Lifetime exposure to psychotropic drugs 
A significant medical or neurological 
illness or history of head injury 
Gross obesity or growth failure 
Full scale IQ lower than 80 
Presence of DSM-IV anorexia nervosa, 
autism, substance use disorder, or 
schizophrenia 
History of maltreatment of axis I 
disorder in controls.  
 
Sexual abuse 
Physical abuse  
Witnessing domestic 
violence.  
K-SADS-PL  
Wechsler 
Intelligence 
Scale for 
Children. 
NG ACC:  NAA/Cr ratio. No difference in Cho/Cr. NAA/Cr calculated 
with LC-Model. 
3 (Schuff et al., 2001) Hippocampi / 210 x 210 x 15 
mm3 
1.5T /PRESS CSI / 1.8 / 135 / 
NG 
18 male PTSD. 
19 male HC. 
Alcohol dependence in the last 5 years 
Illicit drugs prior 5 years 
LOC after head trauma 
Major depression last 3 months 
Antipsychotics last 6 months. 
Combat Veterans SCID (DSM-IV) 
CAPS 
63 Hippocampi: NAA and Cr in both. 
Absence of hippocampal atrophy. 
Absolute (arbitrary 
units). Quantified 
using in house 
software. Partial 
volume corrected 
 
Controlled for alcohol 
dependence (5yrs) 
prior) and found no 
hippocampal atrophy. 
 
4 (Mohanakrishnan Menon et 
al., 2003) 
Hippocampi / 15 x 15 x 15 
mm3 
1.5T / PRESS / 3 / 30 / 128 14 PTSD. 
7 controls (Veterans). 
Seizure disorder 
> 100mg/day Gabapentin 
Severe head injury with LOC 
Uncontrolled diabetes 
Chronic hypertension 
Chronic alcohol or substance abuse 
Stroke. 
Vietnam veterans. Two 
participants with non-
combat trauma. 
Diagnosis made 
according to 
the DSM IV.  
PCL 
CAPS not recorded. Left Hippocampus:  NAA/Cr ratio 
Right hippocampus: no sig difference in NAA/Cr. 
 
No clinical correlations performed. 
tCr used as the 
internal ref. 
 
Hippocampal volume 
was not calculated. 
 
Not controlled for 
handedness, 
medications (other 
than gabapentin), 
recent alcohol or 
substance abuse. No 
regression.  
5 (Villarreal et al., 2002) Hippocampi / 15.3 x 20.3 x 30 
mm3 
Bilateral occipital WM / 20 x 
20 x 21 mm3 
1.5T / PRESS / 2 / 40 / 128 
1.5T / STEAM / 2 / 30 / 128 
8 PTSD. 
5 Healthy controls. 
Major medical or psychiatric diagnosis 
Alcohol or substance dependence 
History of head trauma with LOC 
Seizures 
Neurological Disorder. 
Mixed. Including child 
sexual assault 
SCID-P (DSM-
IV) 
CAPS 
Beck 
Depression 
Inventory 
Beck Anxiety 
Inventory.  
>60 Left hippocampus: Trend to  NAA (p =0.054). 
Occipital WM:  Cr no difference in NAA. 
 
Absolute (arbitrary 
units). Quantified 
using in house 
software.  
 
Hippocampal volume 
not quantified.  
 
No clinical correlates 
performed. 
 
Comorbid depression 
with medication use in 
some participants, 
including 
benzodiazepines.  
Matched for 
handedness.  
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T6 (Brown et al., 2003) Right and left medial temporal lobes / 20 x 20 x 20 
mm3 
1.5T / STEAM / 2 /30 / 128 9 POW + PTSD. 
12 POW – PTSD. 
No history of TBI with LOC 
No neurological impairment 
Degenerative neurological condition 
Dementia.  
No participants met criteria for current 
or lifetime alcohol dependence.  
Former prisoners of war, 
with combat experience. 
CAPS-2 
SCID (DSM-IV) 
72 No significant difference between groups.  
Left MTL: Trend toward  NAA/Cr. 
Negative correlation between NAA/Cr in the MTL 
bilaterally and CAPS-2 re-experiencing symptoms.  
tCr used as internal 
reference. 
 
Controlled for alcohol, 
handedness, alcohol 
dependence. 
 
Brain volumes not 
quantified.  
7 (Lim et al., 2003) Left basal ganglia, right frontal 
periventricular WM and right 
parietal periventricular WM / 
20 x 20 x 20 mm3 
1.5T / STEAM / 3 / 30 / 36 / 
(mixing time 13.7ms) 
16 PTSD (10M:6F). 
8 Healthy controls. 
Organic mental, psychotic, bipolar, 
psychotic or neurological disorders. 
Major head injury (LOC >10min) 
Alcohol or other substance dependence 
in the last year 
No psychotropic medications for the 
previous 4 weeks.  
Fire - Public cafe in Korea 
1999 
SCID -RV 61 Left basal ganglia:  NAA/Cr 
 
FWM: No sig. diff. NAA/Cr or Cho/Cr 
 
PWM: No sig. diff. NAA/Cr or Cho/Cr 
 
No correlation with symptom severity. 
Homogenous 
population. 
 
No partial volume 
correction. 
 
tCr used as the 
internal ref. 
 
Controlled for alcohol 
and medications.  
8 (Kimbrell et al., 2005) Medial temporal lobes /  
20 x 20 x 30 mm3 
1.5T/ STEAM / 2/ 30/ 128 / 
mixing time 13.7ms) 
47 PTSD. 
21 Veteran controls (no 
previous combat exposure). 
 
No head injury with LOC 
Left handed 
No prior neurological illness 
Controls screened for psychological 
illness using SCID. 
War related trauma 
Subdivided into combat 
and non-combat groups. 
SCID (DSM-IV) 
CAPS 
WSM III 
WASI 
MAST 
DAST 
BDI 
SCL-90R 
NG Left MTL: NAA/Cr higher in PTSD-C vs PTSD-NC. 
 
Right MTL: no difference. 
 
No difference between NAA/Cr in the MTL 
between HC and PTSD. 
 
No correlation with NAA/Cr in either MTL and 
severity of PTSD. 
Did not consider other 
traumas. 
 
Cr reference. 
 
No partial volume 
correction.  
 
Did not consider 
childhood abuse.  
 
Significant difference 
between the age of 
subjects and controls 
(44.5 vs 48.4). 
 
Controlled for 
handedness and prior 
mTBI. Matched for 
depression. 
9 (Mahmutyazicioglu et al., 
2005) 
Hippocampi / 30 x 11 x 12 
mm3 
dACC / 30 x 20 x 10 mm3 or 30 
x 15 x 16 mm3 
1.5T / PRESS / 2 / 136 / 128 10 PTSD 
6 Healthy controls 
 
Alcohol or substance abuse during the 
last 6 months.  
Use of drugs of any kind 
Claustrophobia 
Pregnancy 
MR incompatible metal prosthesis / 
implant.  
Antiterrorist combat 
Witnessing the death of a 
friend in a fire 
Childhood sexual abuse 
Trapped in a landslide.  
CAPS 64 Hippocampi:  NAA/Cr and  Cho /Cr 
dACC:  NAA/Cr and no difference in Cho /Cr. 
Visual scoring 
(Scheltens et al) for 
hippocampal atrophy. 
No atrophy reported.  
 
Cr reference. Peaks 
calculated on the 
Phillips scanner.  
 
No partial volume 
correction. Small 
groups. 
 
 
10 (Seedat et al., 2005) ACC / 10 x 10 x 30 mm3 
Left occipital gray matter / 10 
x 10 x 30 mm3. 
1.5T / PRESS / 1.5 / 135 / 256 7 female PTSD. 
9 female trauma exposed 
controls.  
11 non-trauma exposed 
controls. 
Psychotic disorder 
Bipolar disorder 
Psychotropic medications within 6 
weeks 
Substance use disorder within 1 year 
> 2 years of alcohol abuse 
Neurologic disorder or head injury 
associated with cognitive dysfunction 
History of seizure disorder  
ADD or learning disability 
Pregnancy or HIV. 
Intimate partner violence 
- out of relationship for 4 
months but not >2yrs.  
SCID-P (DSM-
IV) 
CTS -2 
Stroop 
CAPS not recorded. ACC:  Cho /Cr and  mI/Cr in PTSD subjects 
when compared to TEC.  
 
ACC: no significant difference when PTSD/TEC’s 
were compared to HC. 
 
Occipital GM: No difference in metabolites. 
 
No correlation with Stroop test or the severity of 
IPV. 
tCr used as the 
internal ref. 
11 (Li et al., 2006) Hippocampi / 15.3 x 20.3 x 40 
mm3 
1.5T / PRESS / 1 / 144 / 248 Prospective case-control 
study.  
12 PTSD. Recent Diagnosis.  
12 Trauma exposed controls. 
No alcohol or other substance use 
disorder within 1 yr.  
No psychotropic medications.  
Fire in Hunan Province 
China. All participants 
exposed to the trauma.  
Psychiatrist 
interview. 
Diagnosed 
according to 
SCID DSM-IV. 
DEQ 
CAPS not recorded. Left hippocampus:  NAA/Cr. 
 
Using VBM identified reduced gray matter 
density of the left hippocampus.  
Didn't measure 
handedness. 
 
tCr and Cho 
metabolite ratios 
calculated. 
 
Small number of 
participants with 
major depression. No 
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mm3 
1.5T / PRESS / 2 / 144 / 128 POW + PTSD 
POW – PTSD 
Control  
 
Female sex 
Left handed 
History of TBI with LOC 
No history of neurological impairment or 
degenerative neurological illness 
Current or lifetime alcohol dependence  
MMSE >26. 
Prisoners of war CAPS-25 
SCID 
Edinburgh 
handedness 
inventory 
Beck 
depression 
inventory  
Davidson 
trauma scale 
Combat 
exposure scale 
Rey Auditory 
Verbal Learning 
Test, Logical 
Memory 
Recognition 
Memory Test 
for Faces.  
POW + PTSD: 53 
POW – PTSD: 14 
Control: 4 
Hippocampi: No statistical difference in NAA/Cr 
or Cho/Cr in either group. 
 
No difference in hippocampal volumes. 
 
Controlled for gender, 
age and education.  
 
Processed using 
SPARC workstation. 
 
Hippocampal volume 
manual determined.  
13 (Ham et al., 2007) ACC / 15 x 15 x 15 mm3 
 
Hippocampi / 15 x 15 x15 
mm3 
3.0T / PRESS / 2 / 35 / 128 26 PTSD subjects. 
25 age and gender matched 
HC. 
Current or past significant medical illness 
Physical injury from fire >10% BSA burn 
LOC during escape 
Any axis I psychiatric diagnosis 
Antisocial or borderline personality 
disorder 
Lifetime exposure to any substance 
other than nicotine, moderate alcohol 
use and caffeine.  
ADHD 
IQ < 80 
Contraindication to MRI scanning.  
Fire in subway train 
Taegu, South Korea. 
February 2003.  
SCID (DSM IV) 
CAPS 
Hamilton 
Depression 
rating scale 
Hamilton 
anxiety rating 
scale.  
71 Hippocampi:  NAA 
 
ACC:   NAA. 
 
No difference in Cr, Cho or mI. 
 
NAA in the ACC negatively correlated with re-
experiencing symptoms. 
 
Did not quantify hippocampal volume.  
Absolute 
quantification 
performed with 
unsuppressed H20. 
14 (Schuff et al., 2008) Hippocampi / 7.8 x 7.8 x 15 
mm3  
 
Frontal and parietal lobes / 
8.5 x 8.5 x 15 mm3 (two slices) 
1.5T / PRESS HMRSI / 1.8/ 35 / 
NG 
PTSD with and without 
alcohol abuse (28 /27). 
 
Trauma exposed controls with 
and without alcohol abuse (23 
/26). 
Past PTSD 
Psychotic disorder 
Bipolar disorder 
Drug abuse or dependence (last 6 
months). 
Neurological illness  
Head trauma with LOC 
Medical disorder affecting brain function 
MRI exclusion criteria 
Brain tumour, small vessel disease, WM 
lesions on MRI. 
Combat 
Military Service 
Civilian events 
Childhood abuse 
CAPS 
SCID (DSM IV) 
LSC-R 
Total 
cumulative 
alcohol over 5 
years. 
CAPS +A group: 66 
CAPS -A group: 63 
Hippocampus: NAA/Cr without smaller 
hippocampal volume (either group.). No 
significant reduction in absolute NAA. 
 
ACC: NAA (absolute) 
  
Alcohol had no significant effect on the brain 
volumes. 
 
Trend toward smaller hippocampal volume in 
subjects with prior childhood trauma. 
 
Depression has no effect on the regression 
model.  
Large groups. Noting 
that data for 19 
subjects was not of 
good quality. 
 
A large number of 
participants in both 
groups had previous 
childhood abuse. 
 
Absolute (arbitrary 
units) concentration 
determined according 
to (Schuff et al., 2001). 
Metabolite ratios also 
calculated, normalised 
to Cr. 
 
ACC region not further 
specified. 
 
 
15 (Guo et al., 2012) Hippocampi / 10 x 10 x 10 
mm3 
 
ACC / 10 x 10 x 10 mm3 
1.5T / PRESS / 1 / 144 / NG 50 PTSD. 
50 heathy controls.  
 
Age and gender matched 
groups.  
 
Antipsychotics, antimanic, 
antidepressant or benzodiazepine drugs. 
History of LOC > 5 minutes 
Clear diagnosis of neurological disease 
Serious body disease 
Clear diagnosis other mental disorder 
History of alcohol or morphine abuse 
History of childhood abuse.  
 
PCL score >=  44  
CAPS > 60 
<1-year duration of PTSD 
 
PCL-C 
CAPS 
WAIS 
 
CAP not reported ACC: NAA/Cr and Cho/Cr. 
 
Hippocampi: NAA/Cr. 
ACC location not 
further specified. 
 
Data analysis 
performed using 
Functool 2 and ACD 
4.0. 
 
tCr used as the 
internal ref. 
 
Volume quantification 
not performed. 
 
16 (Eckart et al., 2012) Hippocampi (medial and 
posterior portion) / 20 x 10 x 
10 mm3 
 
Bilateral insula / 30 x 10 x 15 
mm3 
3.0T / PRESS / 2 / 135 / 256 20 PTSD. 
16 Trauma exposed controls.  
11 Healthy controls.   
 
All male.  
Lifetime or current abuse of substances 
(particularly alcohol) 
Neurologic diseases 
Any contraindication for magnetic 
resonance imaging (MRI)  
Psychiatric conditions other than PTSD 
or major depression.  
 
Highly traumatised 
refugees. Trauma 
exposure occurred at 
mean age of 15.  
CTQ 
Vivo checklist 
of War, 
Detention and 
Torture Events 
CAPS 
MINI 
MP test 
CAPS PTSD: 69 
CAPS: TEC: 14 
No significant difference in the absolute NAA or 
NAA/Cr between PTSD and HC in any brain 
region.  
 
No significant difference in the absolute NAA or 
NAA/Cr between PTSD and TEC in any brain 
region.  
 
No difference in the hippocampi or the insula.  
Absolute 
quantification 
performed with 
unsuppressed H20. LC 
Model. 
 
Partial volume 
correction performed.  
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insula.  
 
Only one PTSD subject 
was taking 
psychoactive 
medications. Co-
morbid major 
depression (n=15 
PTSD). 
 
Inclusion of 
depression as a co-
variate did not alter 
results. 
17 (Shu et al., 2013) Hippocampi / 7.5 x 7.5 x 10 
mm3 
1.5T / PRESS-CSI / 1/ 144 / 2 11 PTSD (right handed). 
11 age, gender and education 
matched HC. 
Bipolar disorder 
Schizophrenia or psychotic disorder 
Alcohol or Substance abuse or 
dependence in past 5years 
Physical or sexual abuse during 
childhood 
Current or past history of neurological 
disease 
Other physical diseases identified by EEG 
or MRI. 
Mixed: including sexual 
assault.  
CAPS Mean CAPS 84.9 Hippocampi:  NAA/Cr 
 
No difference in Cho. 
 
Significant reduction in left and total normalised 
hippocampal volume when compared to controls. 
 
Volume of the left hippocampus was negatively 
correlated with CAPS total and CPAS-C scores. 
 
Serum cortisol negatively correlated with right 
hippocampal NAA/Cr ratio.  
PTSD group receiving 
anti-depressants and 
anti-psychotics. 
 
tCr used as the 
internal ref. 
 
GE ADW Functool 
used to quantify peaks 
area. 
Controlled for 
handedness, age, 
gender and education.  
18 (Rosso et al., 2014) Right Insula / 15 x 30 x 20 
mm3 
 
dACC / 30 x 20 x 20 mm3 
4.0T / MEGA-PRESS / 2 / 68 / 
384 
13 PTSD. 
13 Healthy controls. 
Medical condition: mTBI, LOC, seizures 
Current substance use disorder 
Nicotine use 
Use of benzodiazepines or anxiolytic 
anticonvulsant 
Mood stabiliser or neuroleptic 
medication within 4 weeks of the study 
Substance abuse in the last five years 
Structural abnormality on MRI scan 
Recent psychoactive drug (urine screen). 
Pregnancy. 
Assault 
Childhood physical abuse 
Childhood sexual abuse 
Combat exposure 
Rape 
Multiple traumas 
SCID - I 
CAPS 
STAI-S/T 
BDI 
62 Insula: ↓ GABA/Cr. No association with symptom 
severity. Negative correlation with state and trait 
anxiety. 
 
dACC: GABA/Cr: no difference between groups. 
 
No difference in Cr or NAA. 
Voxel located within 
the dACC.  
 
Spectrum pre-
processed and then 
fitted using LC Model.  
 
tCr used as the 
internal ref. 
 
Matched for 
menstrual cycle. 
Almost all patients 
free of psychotropic 
medications. 
Controlled for drugs, 
nicotine and alcohol.  
19 (Pennington et al., 2014) rACC / 35 x 25 x 20 mm3 
POC / 40 x 20 x 20 mm3 
TEMP / 20 x 40 x 20 mm3 
4.0T / MEGA-PRESS / 2 / 68 / 
384 
 
4.0T / STEAM / NG / 16 / NG 
10 PTSD with AUD. 
28 PTSD  without AUD. 
20 Trauma exposed controls. 
Schizophrenia or schizoaffective disorder 
Past or current alcohol dependence 
(control) 
Suicidal intention 
Bipolar 
Suicidal ideation 
Seizure disorder 
Head injury with (post injury mem loss 
>24hrs or LOC 10min) 
Stroke 
Neurodegenerative condition 
HIV 
Medically unstable 
Psychotropic medication last two weeks. 
 CAPS 
ISI 
AUDIT 
Time line 
follow back 
Beck 
Depression 
Inventory - II 
Beck anxiety 
inventory. 
PAUD: 78.6 
PTSD: 55.2 
CON: 2.7 
TEMP: lower NAA in PAUD than PTSD and TEC. No 
diff PTSD vs TEC. 
 
TEMP and ACC:  Cho in PAUD compared to TEC 
and PTSD. 
 
rACC:  mI in PAUD in ACC when compared to 
TEC and PTSD. 
 
TEMP:  Glx in PAUD vs PTSD. No difference 
PAUD vs. TEC.  
 
POC:  GABA in PAUD vs PTSD. No difference 
PAUD vs. TEC. 
 
Within PAUD, higher GABA and Glu correlated 
with improved cognition.  
Absolute 
concentrations (IU). 
 
ACC voxel contained 
primarily within the 
rostral ACC.  
20 (Michels et al., 2014) 
DLPFC / 25 x 40 x 30 mm3 
rACC / 28 x 30 x 22.5 mm3  
3.0T / MEGA-PRESS / 1.8 / 68 
/ (320 DLPFC and 640 ACC) 
12 PTSD (Some on 
medication). 
17 Trauma exposed controls. 
Free of neurological and other major 
medical conditions.  
Mixed Trauma History 
- PDS 
Childhood 
trauma 
questionnaire 
SCID-I 
SCID-I-R 
CAPS 
Multidimension
al inventory of 
dissociation 
State trait 
anxiety 
67 DLPFC and rACC: 
 GABA/Cr and  glutathione/Cr. 
 
No difference in NAA/Cr or Glx/Cr. 
 
Positive correlation with glutathione and disease 
duration. 
 
 
Voxel located 
primarily within the 
rostral ACC.  
 
tCr used as the 
internal ref. Fitted 
using LC model.  
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Cognitive 
testing 
21 (Meyerhoff et al., 2014) rACC / 35 x 25 x 20 mm3 
POC / 40 x 20 x 20 mm3 
TEMP / 40 x 40 x 20 mm3 
 
4.0T / STEAM / 1.8 / 15 / 128 
4.0T / MEGA-PRESS / 2 / 71 / 
256 
Adults - Military and civilian 
population. 
27 PTSD. 
18 Trauma exposed controls. 
Schizophrenia or schizoaffective disorder 
Alcohol dependence within 6 months 
Bipolar 
Suicidal ideation 
Seizure disorder 
Head injury with (post injury symptoms 
or LOC 10min) 
Stroke 
Neurodegenerative condition 
Medically unstable injuries related to 
trauma. 
Combat (n=17) 
Non-combat (n=10) 
CAPS 
PCL 
Insomnia 
severity index 
(ISI) 
AUDIT 
FTND 
BDI 
BAI 
STAI 
SCL-GSI 
PTSD: 54.5 rACC: ↓NAA  no difference in Glu and GABA. 
 
TEMP: ↓GABA and ↑ Glu. 
 
POC: ↓ GABA and NAA and Glu no difference. 
 
No difference in Cr, Cho or mI in any of the 
groups. 
 
In PTSD POC GABA was negatively correlated with 
ISI (r= -0.55, p=0.008). 
Absolute 
concentration (IU). 
Quantified with ‘SI 
tools’ 
 
Changed the number 
of averages depending 
in SNR (192 vs 256) 
22 (Yang et al., 2015) rACC / 20 x 20 x 20 mm3 3.0T / PRESS / 2 / 30 / 128 Adolescents. 
23 Remitted PTSD. 
10 Healthy controls. 
10 PTSD. 
Smoking 
Alcohol Excess 
Other axis I disorder (except mood / 
anxiety) 
IQ<80 
Psychotropic medication last 4 weeks 
Any sig. medical or neurologic condition. 
Earthquake IQ - Wechsler 
Intelligence 
Scale for 
Chinese 
Children 
CAPS-CA 
C-WISC 
PTSD: 68.7 
Remitted: 5.6 
rACC: Lower Glx/Cr between PTSD group and HC. 
 
Glx lowest in PTSD followed by patients in 
remission. 
 
No difference in NAA/Cr, Cho/Cr,  
 
Glx/Cr was weakly correlated (r=-0.355, p=0.314) 
with CAPS-CA. 
Peaks normalised to 
Cr. Fitted using 
AMARES. 
23 (Harnett et al., 2017) dACC / 20 x 27 x 10 mm3 3T / PRESS / 2 / 30 / 128 19 Trauma exposed 
individuals (physical injury 
requiring visit to trauma unit / 
emergency and exposure to 
traumatic event on the PDS) 
18 Healthy controls  
History of blood or circulation disorders 
Diabetes 
Brain or spinal abnormalities 
Pregnancy 
Previous or current head injury 
Previous / current diagnosis of mental 
illness prior to event. 
 
Physical injury requiring 
visit to trauma unit / 
emergency and exposure 
to traumatic event on the 
PDS. 
PDS (at T0 and 
T1) 
PRFS 
WTAR 
 
 
PDS (1 month): 13 
PDS (3 month): 
12.15 
 
 
No difference between the groups. 
 
Glx Positive linear relationship and current stress 
disorder symptoms in trauma exposed 
participants. 
 
Glx positive linear relationship with future stress 
disorder symptoms.  
 
 
Significant difference 
in participant age (4.5 
years) 
 
Absolute 
concentration. 
Metabolites 
normalised to water.  
Partial volume 
correction performed. 
24 (Rosso et al., 2017) Hippocampi / 15 x 20 x 30 
mm3 
4.0T / 2D JPRESS / 2 / 30 – 
330ms / 16 (4 scans per TE) 
24 PTSD.  
23 Trauma exposed controls.  
 
Age and gender matched. 
Female participants matched 
for menstrual cycle.  
Medical conditions affecting brain 
structure  
Current substance use disorder 
Current nicotine dependence 
Anxiolytic, anticonvulsant, mood 
stabilizing or neuroleptic medication use 
within 4 weeks of study 
History of substance abuse within the 
past 5 years 
Lifetime history of substance 
dependence 
Lifetime history of psychosis 
MR contraindications 
Urine test positive for psychoactive 
drugs or beta-HCG.  
Childhood abuse (n= 5) 
Childhood sexual abuse 
(n=4) 
MVA or violent accident 
(n=2) 
Victim of physical assault 
(n =7) 
Combat exposure (n=1) 
Victims of sexual assault 
(n=9). 
 
SCID / IP 
CAPS 
Traumatic life 
events 
questionnaire.  
PTSD: 59.5 Hippocampi: ↓ NAA/H20 
Right hippocampus: ↑ Glu/H20 and Glu/NAA  
 
Re-experiencing symptoms were negatively 
correlated with all NAA ratios. Significant positive 
correlation between re-experiencing symptoms 
and the right hippocampus Glu / H2O not for 
Glu/Cr. 
 
Trauma load was significantly positively 
correlated with right Glu /NAA in PTSD. 
 
No significant difference in the gray matter 
volume.   
FWHM 8-12 Hz 
 
Metabolites were 
normalised to both 
water, Cr and NAA. 
 
Table 1 -  A summary of the methods and results of the MRS studies included in this review. Abbreviations: 2D-JPRESS – two-dimensional J-resolved 
spectroscopy; ADHD – attention deficit hyperactivity disorder; AUD: Alcohol use disorder; beta-HCG – Human chorionic gonadotropin (pregnancy marker); 
BSA – body surface area; DLPFC – Dorsolateral prefrontal cortex; EEG – electroencephalogram; FWM – Frontal white matter; HC – healthy control; IQ – 
intelligence quotient; K-SADS-PL - Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime version; LOC – loss of 
consciousness; mTBI – mild traumatic brain injury; NA – not applicable; NG – not given; PAUD – PTSD with alcohol use disorder; PCL – PTSD check list; PDS – 
post traumatic diagnostic scale; POC – Posterior occipital cortex; POW – Prisoner of war; PRESS – Point-RESolved Spectroscopy; PRFS – Psychosocial risk factor 
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Tsurvey; PWM – Parietal white matter; STEAM – Stimulated Echo Acquisition Mode; TEC – trauma exposed control; TEMP – lateral temporal cortex;  WM – 
white matter; WTAR – Weschler test of adult reading;. Please go to the individual manuscripts for further details of psychological assessment.  
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Figure 1 – Example of a MRS spectrum from the posterior cingulate gyrus (PCG) of a healthy human brain at 3T, acquired using PRESS (TE = 30ms, TR = 1500ms) with important metabolite resonances labelled. 
Inset: MRS voxel location in the PCG. Adapted with permission from Neurospectroscopy: The Past, Present and Future. Carolyn E. Mountford, Peter Stanwell, Alexander Lin, Saadallah Ramadan, and 
Brian Ross. Chemical Reviews 2010 110 (5), 3060-3086. DOI: 10.1021/cr900250y. Copyright (2010) American Chemical Society.". Abbreviations: Cr – Creatine; Glx – Glutamine and Glutamate; mI – myo-
inositol; Cho – Choline; NAA – N-Acetylaspartate; NAAG - N-actelyaspartylglutamate; MM – macromolecules.  
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Figure 2 - The medial prefrontal cortex (dmPFC: dorsal medial prefrontal cortex and vmPFC: ventromedial prefrontal cortex) with the anterior cingulate cortex (rACC: rostral anterior cingulate cortex and dACC: 
dorsal anterior cingulate cortex) are implicated in the pathogenesis of PTSD. 
 
 
